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Abstract
Background: The most severe clinical form of neurocysticercosis (NC) occurs when cysticerci are located in the
subarachnoid space at the base of the brain (SaB). The diagnosis, monitoring and treatment of NC-SaB, constitutes a severe
clinical challenge. Herein we evaluate the potential of the HP10 antigen detection enzyme-linked immunosorbent assay
(HP10 Ag-ELISA) in the long term follow-up of NC-SaB cases. Assay performance was compared with that of Magnetic
Resonance Imaging (MRI). In addition, the robustness of the HP10 Ag-ELISA was evaluated independently at two different
institutions.
Methodology/Principal Findings: A double-blind prospective cohort trial was conducted involving 38 NC-SaB cases and a
total of 108 paired serum and cerebrospinal fluid (CSF) samples taken at intervals of 4 to 8 months for up to 43 months. At
each medical visit, results of sera and CSF HP10 Ag-ELISA and MRI obtained at last visit were compared and their accuracy
was evaluated retrospectively, considering radiological evolution between appointments. In the long-term follow-up study,
HP10 Ag-ELISA had a better agreement than MRI with retrospective radiological evaluation. High reproducibility of HP10
Ag-ELISA between laboratories was also demonstrated.
Conclusions: Results reported in this study establish for the first time the usefulness of the comparatively low cost HP10 Ag-
ELISA for long term follow-up of NC-SaB patients.
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Introduction
Neurocysticercosis (NC) is one of the most frequent parasitic
diseases affecting the human central nervous system [1]. It is
transmitted by the ingestion of Taenia solium eggs mainly through
the consumption of contaminated vegetables, and is still prevalent
in most countries of Asia, Africa and Latin America, including
Me´xico [2]. Additionally, its prevalence is rising in the United
States and some European countries due to increasing immigra-
tion [3,4].
NC severity critically depends on the location of the parasite.
The disease is mostly benign when cysticerci are located in the
cerebral parenchyma, neuroimaging techniques accurately indi-
cating the number, localization, viability of the parasites and the
intensity of the inflammatory reaction [5,6]. In contrast, when
parasites are located in the basal subarachnoid space (NC-SaB),
clinical presentation is generally severe, cysticidal drugs are less
effective and neuroradiological studies are less precise, diagnosis
relying mostly on indirect clues such as the enlargement of the
basal cisternae [7,8].Furthermore, neuroradiological studies
represent the most expensive healthcare-related costs [9], and
are only available at major urban centres whereas the principal
population at risk is mostly rural.
Detection of the secreted metacestode antigens, particularly
HP10 [10] is becoming an increasingly accepted test for
diagnosing severe NC [11–19]. Previous studies have demonstrat-
ed the high specificity and sensitivity of HP10 antigen ELISA assay
to detect NC-SaB [14–18], and its similar accuracy either when
sera or CSF samples are employed [12,15,18].
In this first prospective long-term study focusing on NC-SaB, we
evaluated the assay reproducibility and accuracy, comparing the
MRI and HP10 results and considering the radiological evolution
of the patients retrospectively at each medical appointment.
Methods
Study cases, MRI examination and sampling
This prospective longitudinal study was performed in a total of
thirty-eight NC-SaB patients who attended to the Instituto
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Nacional de Neurologı´a y Neurocirugı´a (INNN), Mexico City.
The patients included were selected consecutively between August
2008 and March 2010. Initially, fifty patients were included, but 8
were lost in the follow-up as they did not come to the second
medical appointment and, in 4 cases, paired CSF and serum HP10
determinations were not made as their increased intracranial
pressure precluded the taking of CSF samples. Diagnosis was
based on clinical manifestations (presence of focal deficit, affection
of cranial nerves and intracranial hypertension), imaging studies
(MRI with images compatible with the presence of cysticerci, ie.
mainly, enlargement or deformation of a basal cistern or
visualization of cystic vesicles), and HP10 positive in CSF. Patients
were followed-up during 6 to 43 months, resulting in a total of 108
individual clinical, radiological, and serological evaluations. Each
of the 38 cases had received between 1 to 7 cycles of cysticidal
drug treatment before being included in the trial. In most cases
albendazole (ABZ) was used at a dose of 30 mg/kg/day during 8
consecutive days. Few patients received praziquantel (PZQ,
50 mg/kg/day during 10 days) or a combination of ABZ plus
PZQ. Cysticidal drugs were always accompanied with prednisone
(1 mg/kg/day) or dexamethasone (0.4 mg/kg/day), followed by
individual decreasing prednisone doses, depending on the clinical
and inflammatory status.
MRI results (gadolinium-enhanced T1 and T2- weighted and
FLAIR, (Fluid Attenuation Inversion Recovery), MRI sequences)
were recorded, and paired CSF/serum samples were tested for
HP10 Ag-ELISA. Follow-up was carried out at least once in all
cases, at 4–8 month intervals, with further combined HP10 Ag-
ELISA and MRI studies. The time between CSF/serum sampling
for HP10 Ag-ELISA and the associated MRI examination was #1
month. During this time, no cestocidal treatments were admin-
istered.
At each medical visit, changes in MRI studies since last
appointment were assessed and, based on these criteria, the
accuracy of MRI and HP10 results at last evaluation was
established. We considered that patient were free of SaB vesicular
parasites at last evaluation if we did not see any changes in the
suspect images on MRI (absence of disappearance or diminution
in case of specific treatment or enlargement if no cestocidal
treatment was administered). On the other hand, we concluded
that patients present SaB vesicular parasites at their last evaluation
if we observed a reduction of the suspected image after treatment
or its enlargement if treatment had not been administered.
All MRI studies were double-blind interpreted by a certified
neuroradiologist with extensive experience in NC diagnosis. MRI
was considered positive if a vesicular cyst located in the
subarachnoid basal cisterns or a deformation of a cistern
compatible with the presence of a vesicular cyst were observed.
Ethics statement
The study was approved by and carried out under the guidelines
of the Ethical Committee of the Instituto Nacional de Neurologı´a
y Neurocirugı´a, D.F., Me´xico. All patients provided written
informed consent for the collection of samples and subsequent
analysis.
HP10 Ag-ELISA
HP10 Ag-ELISA were blindly performed by two Mexican
laboratories (Instituto de Investigaciones Biomedicas, UNAM
(IIB), and INNN), both in Mexico City, Mexico. Afterwards,
sample codes were revealed and results were analyzed.
HP10 antigen was detected by Ag-ELISA as described
previously [10]. All samples were run in duplicate by two
experimented technicians. Briefly, plates (Nunc, Rochester, New
York, USA) were coated with monoclonal antibody (MoAb) HP10
(100 ml at 10 mg/ml in 0.07 M NaCl buffered with 0.1 M borate,
pH 8.2) and left overnight at 4uC, washed four times with 200 ml/
well of wash solution (0.9% w/v NaCl containing 0.05%v/v
Tween 20) and then blocked using 200 ml of phosphate-buffered
saline containing bovine serum albumin (Roche, Me´xico) (1.0%
w/v and 0.05% v/v Tween 20) and left by 60 min at room
temperature before being washed in a similar way. Undiluted CSF
or serum samples (100 ml/well) were added and incubated 30 min
at 37uC. Bound HP10 parasite antigen was detected using
biotinylated MoAb HP10 (2 mg/ml in diluent, for 60 min at
37uC), horseradish peroxidase-conjugated streptavidin (Zymed,
San Francisco, California, USA) (1:4000 in diluent, 30 min at
37uC) and tetramethylbenzidine (Zymed, San Francisco, Califor-
nia, USA) as substrate. Color reaction was allowed to proceed for
30 min at 4uC in the dark and was stopped by adding 100 ml 0.2
M H2SO4 (Baker, Estado de Mexico, Mexico). Optical densities
(OD; 450 nm) were determined in an ELISA processor (at INNN:
Bio-Rad Microplate Reader Benchmark, Hercules, California,
USA; at IIBM: Opsys MR Dynex Technology, Chantilly,
Virginia, USA).
A sample was considered positive if the mean OD at 450 nm
value was higher than the cut off value, which was calculated
based on the mean of the OD plus 2 SD of CSF and sera from
non-NC controls.
Statistical analysis
A database was built using Excel 7.0 (Microsoft) software. MRI
findings and CSF/serum HP10 levels were recorded. Statistical
analysis was made using SPSS 10.0 (Microsoft), Epidat 3.0 and
SAS 9.0 softwares. Parametric statistics (mean and SD) were
calculated. Kappa coefficient (k) and 95% confidence intervals
were calculated to evaluate the qualitative agreement between
HP10 results in CSF and sera and between institutions. This
coefficient varied between 21 and +1. The closer the value is to1,
the stronger the agreement [20]. Generalized Estimating Equa-
tions (GEE) analysis [21] was performed in order to confirm
agreement taking into account repeated observations and
variability of period of time between appointments. Results
Author Summary
Neurocysticercosis is one of the most frequent parasitic
diseases affecting the human central nervous system. The
most severe clinical forms occur when parasites are
located in the subarachnoid space at the base of the
brain. In these instances, cysticidal drug efficacy is reduced
and neuroimaging studies are less reliable as diagnostic
tools. Previous works highlighted the value of antigen
detection by ELISA test to detect viable parasites in these
locations. In this prospective study, we evaluate its utility
in patient follow-up, comparing its performance with
magnetic resonance imaging results. Results from both
procedures were also compared retrospectively at each
medical appointment considering radiological evolution
since last evaluation. Thirty-eight patients were included,
with a total of 108 samples collected over 43 months. We
demonstrated that antigen detection in these patients is
an accurate tool in determining the efficacy of cysticidal
treatment. This result is of great potential, considering the
difficulty for the patients in endemic countries to access
imaging studies and the much lower cost of the assay with
respect to magnetic resonance imaging.
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confirm that these two factors did not modify the agreement
between tests.
Results
Summary of case descriptions
The main features of the 38 patients included in the study are
summarized in table 1. Most patients had vesicular cysticerci
located in the SaB with inflammatory CSF, in spite of the previous
cysticidal treatment.
Reproducibility between institutions in assay
performance
Kappa analysis indicated a good to very good level of agreement
between positive/negative allocations comparing results obtained
in both institutions (CSF Kappa: 0.86 [0.75–0.97, P,0.0001] and
serum Kappa: 0.76 [0.64–0.89, P,0.0001]) [15].
HP10-ELISA performed equally well in CSF than in serum
A good level of agreement15 between positive/negative alloca-
tions for paired CSF and serum samples (CSF/serum IIBM
Kappa: 0.63 [0.48–0.79, P,0.0001] and CSF/serum INNN
Kappa: 0.64 [0.49–0.79, P,0.0001]) was found.
Comparison of MRI and CSF HP10 Ag-ELISA results
There was complete agreement between radiological and CSF
HP10 Ag-ELISA results in 18 out of the 38 cases (50 samples).
As shown in table 2, as judged by negative MRI and CSF HP10
Ag-ELISA results, the infection resolved only in three of these
cases. In the other 15 cases, cysticerci persisted and so additional
ABZ cycles were indicated.
Of the remaining 20 patients without complete agreement
between MRI and CSF HP10 Ag-ELISA assays in all samples,
discordant results were found in 32 of the 58 samples (55.2%).
Comparison of MRI and sera HP10 Ag-ELISA results
As shown in table 3, a complete agreement between HP10 Ag-
ELISA in sera and MRI evaluation was obtained in 14 patients,
corresponding to 38 paired samples. In the remaining 24 patients,
disagreement was observed in some of the samples (43 of 70, 61%).
Comparison of MRI and retrospective radiological
evolution
As shown in table 4, agreement between MRI results and
retrospective evaluation taking in count radiological evolution
between appointment was moderate: Kappa: 0.45 (0.26–0.63). In
24 samples, divergent results occurred: 15 of them with positive
results in MRI and negative results in retrospective evaluation, and
the reverse in 9 of them.
Comparison of CSF HP10 Ag-ELISA and retrospective
radiological evolution
As shown in table 5, agreement between CSF HP10 Ag-ELISA
results and retrospective evaluation taking in count clinical and
radiological evolution was very good: Kappa: 0.82 (0.70–0.94).
Differences between the evaluations occurred in only 8 samples,
with positive results in HP10 Ag-ELISA/negative results in
retrospective clinical/radiological evaluations in 6 and the reverse
in two.
Comparison of sera HP10 Ag-ELISA and retrospective
radiological evolution
As shown in table 6, the agreement between sera HP10 Ag-
ELISA results and retrospective evaluation taking in count clinical
and radiological evaluation was moderate: Kappa: 0.56 (0.39–
0.73). Differences between the evaluations occurred in 21 samples,
with positive results in sera HP10 Ag-ELISA/negative results in
retrospective clinical/radiological evaluations in 8 and the reverse
in 13.
Discussion
Diagnosis of NC- SaB is still a challenge. In previous studies, it
was demonstrated that the levels of secreted cysticercal HP10
antigen in CSF and serum is an accurate method to diagnose
vesicular cysticerci located in the ventricles or SaB [11–15]. HP10
Ag-ELISA was originally designed to diagnose Taenia saginata
cysticercosis [10], but since HP10 antigen is shared by other
Table 1. Main features of the 38 patients included in the
study.
Sex (Male/Female) 24/14
Percent of patients with vesicular cysticerci in SaB 63% (24/38)
Age 29–67 (46.3610.8)*
Number of cysticidal cycles received before inclusion 0–8 (2.462.0)*
CSF cellularity at inclusion 1–343 (58.9667.3)*
Number of samples per patient 2–5 (2.161.0)*
Months of follow-up 6–39 (27.269.1)*
*Range (mean6SD).
doi:10.1371/journal.pntd.0002096.t001
Table 2. Main features of the 18 patients with complete agreement between CSF HP10 Ag-ELISA and MRI evaluation.
Number of evaluations per patient* Number of patients (total number of evaluations) Results of last evaluations
2 9 (18) 9 positives{
3 5 (15) 3 positives/2 negatives
4 3 (12) 2 positives/1 negative
5 1 (5) 1 positive
Total: 18 (50) 15 positives/3 negatives
*Evaluations refer to the paired realization in each patient of MRI and of HP10 determination in CSF and serum. The results of HP10 considered in this table are those
obtained at IIB in CSF.
{Positive: persistence of vesicular cysticerci in SaB (using MRI or HP10 antigen levels)/Negative: No detectable vesicular cysticerci in SaB (using MRI or HP10 antigen
levels).
doi:10.1371/journal.pntd.0002096.t002
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cestodes such as T. solium, it is also useful for NC diagnosis [11–
15].
In this prospective longitudinal study, we evaluated the
usefulness of the HP10 Ag-ELISA assay in the follow-up of
patients with NC-SaB, and compared its predictive capacity with
MRI, the best tool currently available for the diagnosis and follow-
up of these patients. Both tests were compared with a retrospective
diagnosis based on radiological evolution between medical
appointments.
The results obtained herein demonstrate the usefulness of HP10
Ag-ELISA for the follow-up of severe NC-SaB patients. Of the 108
paired MRI/HP10 Ag-ELISA evaluations, agreement between
MRI and CSF HP10 Ag-ELISA was found in 76 (70.4%) and
between MRI and sera HP10 in 65 (60%). Retrospective analysis
evaluating at each medical appointment the radiological evolution
between visits shows that this lack of agreement appears to be
principally due to a misinterpreted MRI rather than to serum
and/or CSF HP10 Ag-ELISA assay. In addition, HP10 Ag-ELISA
proved to be a highly reproducible method, as high Kappa
coefficients of 0.76 and 0.86 in sera and CSF, respectively, were
obtained when comparing results obtained in two different
Mexican institutions.
Another result meriting comment is the confirmation that
determination of HP10 in sera is of interest, giving quite similar
agreement than MRI with retrospective diagnosis. Agreement
between CSF HP10 determination and retrospective evaluation
was higher, but considering the invasive nature of the lumbar
puncture, procedure necessary to collect CSF, the use of sera
instead of CSF could be recommended, particularly if there is no
clinical emergency, and also for monitoring of SaB neurocysticer-
cosis patients from rural communities where imaging facilities are
not available.
Considering these results, it is possible to propose HP10
determination in order to reduce the number of MRI required
in the follow-up of such patients. Generally, MRIs are realized
each 6 months to evaluate response to treatment, and frequently 4
to more than 8 studies are made by patient during their illness and
treatment. The results herein presented show that it will be
possible to reduce the number of studies to at least a half without
taking a risk of misdiagnosis. We recommend that after diagnosis
of NC-SaB by MRI (diagnosis must be made by MRI as it will
permit the evaluation of the extent of the disease), the follow-up of
the patients could be made by one MRI and one HP10 evaluation
each year until parasites disappears. Election of serum or CSF
HP10 evaluation, as said before, will depend on the gravity of the
patients and the possibility to make lumbar puncture without risk.
Importantly, the results obtained in this study point to the need
for improving MRI for NC diagnosis. As shown here, when
cysticerci are located in the SaB, diagnostic radiology techniques
are imprecise. This can be explained by the fact that parasites emit
a signal of similar intensity than the CSF itself. In addition, in most
cases the image is not enhanced by administration of intravenous
contrast, and finally, metacestodes commonly lack the distinguish-
ing scolex that allows their identification [8]. In this respect, new
MRI technologies based on a fast imaging employing steady-state
acquisition (FIESTA) has shown to have a good capacity to
diagnose intraventricular cysts because of their high spatial
resolution and signal-to-noise rate [22]. Nevertheless, despite the
promising results reported, these procedures are not yet standard-
ized for NC diagnosis. It is also interesting to note that FLAIR
sequences, permitting better visualization of the scolex and the cyst
wall, did not resolve all the cases in our studies [5,23].
The need for an economic and reliable diagnosis of cysticercosis
is now of urgent concern in rural cysticercosis endemic commu-
nities, particularly as recent plans for the control of neglected
tropical diseases, such as schistosomiasis, involve the mass and
indiscriminate dosing of entire African populations with anti-
helmintic drugs, including praziquantel [24]. Such treatment, of
population co-infected with T. solium neurocysticercosis, would be
predicted to increase the inflammation around the cyst, thereby
Table 3. Main features of the 14 patients with complete agreement between sera HP10 Ag-ELISA and MRI evaluations.
Number of evaluations per patient* Number of patients (total number of evaluations) Results of last evaluation
2 8 (16) 7 positives/1 negative{
3 3 (9) 3 positives
4 2 (8) 2 positives
5 1 (5) 1 positive
Total: 14 (38) 13 positives/1 negative
*Evaluations refer to the paired realization in each patient of MRI and of HP10 determinations in sera obtained at IIB.
{Positive: persistence of vesicular cysticerci in SaB (using MRI or HP10 levels)/Negative: No detectable vesicular cysticerci in SaB (using MRI or HP10 levels).
doi:10.1371/journal.pntd.0002096.t003
Table 4. Agreement analysis between MRI results and
retrospective evaluation.
Retrospective evaluation Total
Presence of
parasites
Absence of
parasites
MRI Presence of parasites 66 15 81
Absence of parasites 9 18 27
Total 75 33 108
doi:10.1371/journal.pntd.0002096.t004
Table 5. Agreement analysis between CSF HP10 results and
retrospective evaluation.
Retrospective evaluation Total
Presence of
parasites
Absence of
parasites
HP10 CSF Positive 73 6 79
Negative 2 27 29
Total 75 33 108
doi:10.1371/journal.pntd.0002096.t005
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provoking severe side effects [25–27]. Thus a prior screening for
cysticercosis/neurocysticercosis, ideally including antibody and
antigen detection, might be advisable.
Neuroradiological studies required for diagnosis and patient
follow-up currently represent the main cost of NC management in
particular in severe NC-SaB, which usually requires multiple
cysticidal cycles of treatment [9]. Thus, the alternative use of a
serological non-invasive, non-expensive, highly accurate assay
could have a real economic impact. To illustrate this point, is
worthy to mention that an MRI in Mexico costs approximately
400 dollars, a cost dramatically contrasting with approximately 1–
10 dollars for a typical commercial Ag-ELISA test. HP10 ELISA
could have an undeniably positive economic impact for the patient
and for the health institutions as well. This study offers arguments
to strongly recommend its routine use for the follow-up of these
severely affected patients.
Despite the HP10 Ag-ELISA accuracy, HP10 false positive
results would lead to unnecessary treatment of these patients
(being corticoid administration the main problem).Thus, it is
urgent to investigate the factors underlying false positive results.
False negative HP10 results were observed only in 2 of the 108
evaluations (1.8%) in CSF and in 13 (12%) in serum, posing a very
low risk of failing to discriminate a NC-SaB patient still requiring
treatment. To avoid the risk of incomplete drug treatment, we
suggest repeating serum HP10 Ag-ELISA test in patients
presenting NC-SaB with HP10-negative results after treatment.
It is important to note that these results must be confirmed.
Limitations of this study are mainly due to: 1) the small number of
patients that leads to large confidence intervals and uncertainty.
However, it must be stated that these types of patients (NC-SaB)
are infrequent and that this study is the first one with such large
follow-up; 2) the retrospective diagnosis can be criticized as it is
known that evolution of parasites is very slow. It is possible that in
some cases, for example, radiological picture of the patients did
not change between 2 appointments mistakenly making believe
that there were no parasites although there were present. We are
conscious of this fact and we hope that the standardization of new
MRI techniques will permit to give new tools to evaluate these
tests.
In conclusion, this study establishes the usefulness and economic
advantage of the HP10 Ag-ELISA applied on CSF and serum
samples for the follow-up of patients with NC-SaB, the most severe
form of the disease. Hopefully, these results will lead to the rapid
commercialization of a HP10 antigen diagnostic kit to favor its
employment worldwide.
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